{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:30:53Z","timestamp":1793374253077,"version":"4.5.0"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T00:00:00Z","timestamp":1644796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T00:00:00Z","timestamp":1644796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"The University of Alberta funded open access publication of this article.","id":[{"id":"https:\/\/ror.org\/0160cpw27","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s40263-022-00897-2","type":"journal-article","created":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T13:02:59Z","timestamp":1644843779000},"page":"239-251","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Non-parenteral Ketamine for Depression: A Practical Discussion on Addiction Potential and Recommendations for Judicious Prescribing"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6071-1395","authenticated-orcid":false,"given":"Jennifer","family":"Swainson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry J.","family":"Klassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratap","family":"Chokka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin A.","family":"Katzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Tanguay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Khullar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,14]]},"reference":[{"key":"897_CR1","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1177\/0706743716659416","volume":"61","author":"RW Lam","year":"2016","unstructured":"Lam RW, McIntosh D, Wang J, Enns MW, Kolivakis T, Michalak EE, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder. Can J Psychiatry Rev Can Psychiatry. 2016;61:510\u201323.","journal-title":"Can J Psychiatry Rev Can Psychiatry"},{"key":"897_CR2","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1177\/0706743716659418","volume":"61","author":"SV Parikh","year":"2016","unstructured":"Parikh SV, Quilty LC, Ravitz P, Rosenbluth M, Pavlova B, Grigoriadis S, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 2. Psychological treatments. Can J Psychiatry Rev Can Psychiatry. 2016;61:524\u201339.","journal-title":"Can J Psychiatry Rev Can Psychiatry"},{"key":"897_CR3","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","volume":"163","author":"AJ Rush","year":"2006","unstructured":"Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163:1905\u201317.","journal-title":"Am J Psychiatry"},{"key":"897_CR4","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/0706743720970860","volume":"66","author":"J Swainson","year":"2021","unstructured":"Swainson J, McGirr A, Blier P, Brietzke E, Richard-Devantoy S, Ravindran N, et al. The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force recommendations for the use of racemic ketamine in adults with major depressive disorder. Can J Psychiatry. 2021;66:113\u201325.","journal-title":"Can J Psychiatry"},{"key":"897_CR5","unstructured":"Pharmacoeconomic Report: Esketamine Hydrochloride (Spravato): (Janssen Inc.): Indication: Major Depressive Disorder in Adults [Internet]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2021 Apr. Appendix 1, Cost Comparison Table. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK572205\/."},{"key":"897_CR6","unstructured":"Janssen Pharmaceuticals Inc. Spravato (esketamine) nasal spray. Prescribing Information. [Internet]; 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/211243s004lbl.pdf."},{"key":"897_CR7","unstructured":"Janssen-Cilag International NV. Summary of Product Characteristics. Spravato 28 mg nasal spray, solution (esketamine). [Internet]; 2019 [cited 2021 Nov 9]. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/spravato-epar-product-information_en.pdf."},{"issue":"12","key":"897_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.549080","volume":"24","author":"J Vankawala","year":"2021","unstructured":"Vankawala J, Naples G, Avila-Quintero VJ, Ram\u00edrez KL, Flores JM, Bloch MH, Dwyer JB. Meta-analysis: Hemodynamic responses to sub-anesthetic doses of ketamine in patients with psychiatric disorders. Front Psychiatry. 2021;24(12): 549080. https:\/\/doi.org\/10.3389\/fpsyt.2021.549080.","journal-title":"Front Psychiatry"},{"key":"897_CR9","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1001\/jamapsychiatry.2017.0080","volume":"74","author":"G Sanacora","year":"2017","unstructured":"Sanacora G, Frye MA, McDonald W, Mathew SJ, Turner MS, Schatzberg AF, et al. A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry. 2017;74:399\u2013405.","journal-title":"JAMA Psychiatry"},{"key":"897_CR10","unstructured":"Royal College of Psychiatrists, Committee on ECt and Related Treatments. Statement on ketamine to treat depression [Internet]; 2017 [cited 2021 Mar 31]. https:\/\/www.rcpsych.ac.uk\/docs\/default-source\/about-us\/who-we-are\/ectcommittee-ketamine-to-treat-depression-statement-feb17.pdf?sfvrsn=db4e7a95_2."},{"key":"897_CR11","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1176\/appi.ajp.2020.20081251","volume":"178","author":"RS McIntyre","year":"2021","unstructured":"McIntyre RS, Rosenblat JD, Nemeroff CB, Sanacora G, Murrough JW, Berk M, et al. Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation. Am J Psychiatry. 2021;178:383\u201399.","journal-title":"Am J Psychiatry"},{"key":"897_CR12","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/bdi.12609","volume":"20","author":"LN Yatham","year":"2018","unstructured":"Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ, Frey BN, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20:97\u2013170.","journal-title":"Bipolar Disord"},{"key":"897_CR13","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1176\/appi.ajp.2020.20050596","volume":"178","author":"A Feder","year":"2021","unstructured":"Feder A, Costi S, Rutter SB, Collins AB, Govindarajulu U, Jha MK, et al. A Randomized controlled trial of repeated ketamine administration for chronic posttraumatic stress disorder. Am J Psychiatry. 2021;178:193\u2013202.","journal-title":"Am J Psychiatry"},{"key":"897_CR14","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4103\/IJPSYM.IJPSYM_228_19","volume":"42","author":"CS Gautam","year":"2020","unstructured":"Gautam CS, Mahajan SS, Sharma J, Singh H, Singh J. Repurposing potential of ketamine: opportunities and challenges. Indian J Psychol Med. 2020;42:22\u20139.","journal-title":"Indian J Psychol Med."},{"key":"897_CR15","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/pcn.12902","volume":"73","author":"K Hashimoto","year":"2019","unstructured":"Hashimoto K. Rapid-acting antidepressant ketamine, its metabolites and other candidates: a historical overview and future perspective. Psychiatry Clin Neurosci. 2019;73:613\u201327.","journal-title":"Psychiatry Clin Neurosci"},{"key":"897_CR16","doi-asserted-by":"crossref","first-page":"283","DOI":"10.4103\/0259-1162.143110","volume":"8","author":"MS Kurdi","year":"2014","unstructured":"Kurdi MS, Theerth KA, Deva RS. Ketamine: current applications in anesthesia, pain, and critical care. Anesth Essays Res. 2014;8:283\u201390.","journal-title":"Anesth Essays Res"},{"key":"897_CR17","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1038\/npp.2013.150","volume":"38","author":"CI Rodriguez","year":"2013","unstructured":"Rodriguez CI, Kegeles LS, Levinson A, Feng T, Marcus SM, Vermes D, et al. Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2013;38:2475\u201383.","journal-title":"Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol"},{"key":"897_CR18","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1176\/appi.ajp.2017.17040472","volume":"175","author":"ST Wilkinson","year":"2018","unstructured":"Wilkinson ST, Ballard ED, Bloch MH, Mathew SJ, Murrough JW, Feder A, et al. The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis. Am J Psychiatry. 2018;175:150\u20138.","journal-title":"Am J Psychiatry"},{"key":"897_CR19","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/02791072.2019.1587556","volume":"51","author":"J Dore","year":"2019","unstructured":"Dore J, Turnipseed B, Dwyer S, Turnipseed A, Andries J, Ascani G, et al. Ketamine assisted psychotherapy (KAP): patient demographics, clinical data and outcomes in three large practices administering ketamine with psychotherapy. J Psychoactive Drugs. 2019;51:189\u201398.","journal-title":"J Psychoactive Drugs"},{"key":"897_CR20","doi-asserted-by":"crossref","first-page":"13514","DOI":"10.1021\/acs.jmedchem.0c01193","volume":"63","author":"J Das","year":"2020","unstructured":"Das J. Repurposing of drugs\u2014the ketamine story. J Med Chem. 2020;63:13514\u201325.","journal-title":"J Med Chem"},{"key":"897_CR21","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1017\/S0033291714001603","volume":"45","author":"A McGirr","year":"2015","unstructured":"McGirr A, Berlim MT, Bond DJ, Fleck MP, Yatham LN, Lam RW. A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychol Med. 2015;45:693\u2013704.","journal-title":"Psychol Med"},{"key":"897_CR22","doi-asserted-by":"crossref","first-page":"18r12475","DOI":"10.4088\/JCP.18r12475","volume":"80","author":"JD Rosenblat","year":"2019","unstructured":"Rosenblat JD, Carvalho AF, Li M, Lee Y, Subramanieapillai M, McIntyre RS. Oral ketamine for depression: a systematic review. J Clin Psychiatry. 2019;80:18r12475.","journal-title":"J Clin Psychiatry"},{"key":"897_CR23","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jad.2020.01.002","volume":"265","author":"W Zheng","year":"2020","unstructured":"Zheng W, Cai D-B, Xiang Y-Q, Zheng W, Jiang W-L, Sim K, et al. Adjunctive intranasal esketamine for major depressive disorder: a systematic review of randomized double-blind controlled-placebo studies. J Affect Disord. 2020;265:63\u201370.","journal-title":"J Affect Disord"},{"key":"897_CR24","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2215-0366(17)30272-9","volume":"5","author":"B Short","year":"2018","unstructured":"Short B, Fong J, Galvez V, Shelker W, Loo CK. Side-effects associated with ketamine use in depression: a systematic review. Lancet Psychiatry. 2018;5:65\u201378.","journal-title":"Lancet Psychiatry"},{"key":"897_CR25","doi-asserted-by":"crossref","first-page":"247","DOI":"10.4088\/JCP.13m08852","volume":"76","author":"L-B Wan","year":"2015","unstructured":"Wan L-B, Levitch CF, Perez AM, Brallier JW, Iosifescu DV, Chang LC, et al. Ketamine safety and tolerability in clinical trials for treatment-resistant depression. J Clin Psychiatry. 2015;76:247\u201352.","journal-title":"J Clin Psychiatry"},{"key":"897_CR26","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1177\/0706743716659417","volume":"61","author":"SH Kennedy","year":"2016","unstructured":"Kennedy SH, Lam RW, McIntyre RS, Tourjman SV, Bhat V, Blier P, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder. Can J Psychiatry Rev Can Psychiatry. 2016;61:540\u201360.","journal-title":"Can J Psychiatry Rev Can Psychiatry"},{"key":"897_CR27","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1177\/0706743716660033","volume":"61","author":"RV Milev","year":"2016","unstructured":"Milev RV, Giacobbe P, Kennedy SH, Blumberger DM, Daskalakis ZJ, Downar J, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder. Can J Psychiatry Rev Can Psychiatry. 2016;61:561\u201375.","journal-title":"Can J Psychiatry Rev Can Psychiatry"},{"key":"897_CR28","volume":"78","author":"C Andrade","year":"2017","unstructured":"Andrade C. Ketamine for depression, 4: in what dose, at what rate, by what route, for how long, and at what frequency? J Clin Psychiatry. 2017;78: e852-7.","journal-title":"J Clin Psychiatry"},{"key":"897_CR29","first-page":"1912838","volume":"80","author":"C Andrade","year":"2019","unstructured":"Andrade C. Oral ketamine for depression, 2: practical considerations. J Clin Psychiatry. 2019;80:1912838.","journal-title":"J Clin Psychiatry"},{"key":"897_CR30","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/JCP.0000000000000894","volume":"38","author":"S Archer","year":"2018","unstructured":"Archer S, Chrenek C, Swainson J. Maintenance ketamine therapy for treatment-resistant depression. J Clin Psychopharmacol. 2018;38:380\u20134.","journal-title":"J Clin Psychopharmacol"},{"key":"897_CR31","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1177\/0269881118822160","volume":"33","author":"V Lee","year":"2019","unstructured":"Lee V, Archer S, Chrenek C, Swainson J. A response to: Repeated intranasal ketamine for treatment resistant depression: the way to go? Results from a pilot randomised controlled trial. J Psychopharmacol Oxf Engl. 2019;33:258\u20139.","journal-title":"J Psychopharmacol Oxf Engl"},{"key":"897_CR32","first-page":"19lr13146","volume":"81","author":"J Swainson","year":"2020","unstructured":"Swainson J, Khullar A. Sublingual ketamine: an option for increasing accessibility of ketamine treatments for depression? J Clin Psychiatry. 2020;81:19lr13146.","journal-title":"J Clin Psychiatry"},{"key":"897_CR33","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jad.2018.02.025","volume":"236","author":"P Riva-Posse","year":"2018","unstructured":"Riva-Posse P, Reiff CM, Edwards JA, Job GP, Galendez GC, Garlow SJ, et al. Blood pressure safety of subanesthetic ketamine for depression: a report on 684 infusions. J Affect Disord. 2018;236:291\u20137.","journal-title":"J Affect Disord"},{"key":"897_CR34","doi-asserted-by":"crossref","first-page":"253","DOI":"10.4088\/JCP.v66n0215","volume":"66","author":"TE Wilens","year":"2005","unstructured":"Wilens TE, Hammerness PG, Biederman J, Kwon A, Spencer TJ, Clark S, et al. Blood pressure changes associated with medication treatment of adults with attention-deficit\/hyperactivity disorder. J Clin Psychiatry. 2005;66:253\u20139.","journal-title":"J Clin Psychiatry"},{"key":"897_CR35","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1007\/s00213-020-05611-y","volume":"237","author":"H Findeis","year":"2020","unstructured":"Findeis H, Sauer C, Cleare A, Bauer M, Ritter P. Urothelial toxicity of esketamine in the treatment of depression. Psychopharmacology. 2020;237:3295\u2013302.","journal-title":"Psychopharmacology"},{"key":"897_CR36","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/jps.2600710516","volume":"71","author":"JA Clements","year":"1982","unstructured":"Clements JA, Nimmo WS, Grant IS. Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans. J Pharm Sci. 1982;71:539\u201342.","journal-title":"J Pharm Sci"},{"key":"897_CR37","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1111\/bcp.12264","volume":"77","author":"P Rolan","year":"2014","unstructured":"Rolan P, Lim S, Sunderland V, Liu Y, Molnar V. The absolute bioavailability of racemic ketamine from a novel sublingual formulation. Br J Clin Pharmacol. 2014;77:1011\u20136.","journal-title":"Br J Clin Pharmacol"},{"key":"897_CR38","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1093\/bja\/77.2.203","volume":"77","author":"JM Malinovsky","year":"1996","unstructured":"Malinovsky JM, Servin F, Cozian A, Lepage JY, Pinaud M. Ketamine and norketamine plasma concentrations after i.v., nasal and rectal administration in children. Br J Anaesth. 1996;77:203\u20137.","journal-title":"Br J Anaesth"},{"key":"897_CR39","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1097\/JCP.0000000000000717","volume":"37","author":"MI Al Shirawi","year":"2017","unstructured":"Al Shirawi MI, Kennedy SH, Ho KT, Byrne R, Downar J. Oral ketamine in treatment-resistant depression. J Clin Psychopharmacol. 2017;37:464\u20137.","journal-title":"J Clin Psychopharmacol"},{"key":"897_CR40","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00213-017-4786-3","volume":"235","author":"J Hartberg","year":"2018","unstructured":"Hartberg J, Garrett-Walcott S, De Gioannis A. Impact of oral ketamine augmentation on hospital admissions in treatment-resistant depression and PTSD: a retrospective study. Psychopharmacology. 2018;235:393\u20138.","journal-title":"Psychopharmacology"},{"key":"897_CR41","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1192\/bjp.2018.196","volume":"214","author":"Y Domany","year":"2019","unstructured":"Domany Y, Bleich-Cohen M, Tarrasch R, Meidan R, Litvak-Lazar O, Stoppleman N, et al. Repeated oral ketamine for out-patient treatment of resistant depression: randomised, double-blind, placebo-controlled, proof-of-concept study. Br J Psychiatry J Ment Sci. 2019;214:20\u20136.","journal-title":"Br J Psychiatry J Ment Sci"},{"key":"897_CR42","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.biopsych.2014.03.026","volume":"76","author":"KAB Lapidus","year":"2014","unstructured":"Lapidus KAB, Levitch CF, Perez AM, Brallier JW, Parides MK, Soleimani L, et al. A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry. 2014;76:970\u20136.","journal-title":"Biol Psychiatry"},{"key":"897_CR43","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1177\/0269881118760660","volume":"32","author":"V G\u00e1lvez","year":"2018","unstructured":"G\u00e1lvez V, Li A, Huggins C, Glue P, Martin D, Somogyi AA, et al. Repeated intranasal ketamine for treatment-resistant depression\u2014the way to go? Results from a pilot randomised controlled trial. J Psychopharmacol Oxf Engl. 2018;32:397\u2013407.","journal-title":"J Psychopharmacol Oxf Engl"},{"key":"897_CR44","unstructured":"Jazz Pharmaceuticals Ireland Limited. XYREM(R) (sodium oxybate oral solution) Product Monograph. [Internet]; 2018. https:\/\/pp.jazzpharma.com\/pi\/xyrem.ca.PM-en.pdf."},{"key":"897_CR45","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/da.22536","volume":"33","author":"S Sassano-Higgins","year":"2016","unstructured":"Sassano-Higgins S, Baron D, Juarez G, Esmaili N, Gold M. A Review of ketamine abuse and diversion. Depress Anxiety. 2016;33:718\u201327.","journal-title":"Depress Anxiety"},{"key":"897_CR46","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.drugalcdep.2008.01.024","volume":"95","author":"L Muetzelfeldt","year":"2008","unstructured":"Muetzelfeldt L, Kamboj SK, Rees H, Taylor J, Morgan CJA, Curran HV. Journey through the K-hole: phenomenological aspects of ketamine use. Drug Alcohol Depend. 2008;95:219\u201329.","journal-title":"Drug Alcohol Depend"},{"key":"897_CR47","first-page":"185","volume":"114","author":"MJ Shram","year":"2011","unstructured":"Shram MJ, Sellers EM, Romach MK. Oral ketamine as a positive control in human abuse potential studies. Drug Alcohol Depend. 2011;114:185\u201393.","journal-title":"Drug Alcohol Depend"},{"key":"897_CR48","unstructured":"World Health Organization. Critical Review Report. Ketamine. 34th ECDD. 2006;30."},{"key":"897_CR49","unstructured":"National Institute on Drug Abuse. The Science of Drug Use and Addiction: The Basics [Internet]. National Institutes of Health; 2018 [cited 2020 Nov 2]. https:\/\/www.drugabuse.gov\/publications\/media-guide\/science-drug-use-addiction-basics."},{"key":"897_CR50","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1159\/000506868","volume":"89","author":"F Cosci","year":"2020","unstructured":"Cosci F, Chouinard G. Acute and persistent withdrawal syndromes following discontinuation of psychotropic medications. Psychother Psychosom. 2020;89:283\u2013306.","journal-title":"Psychother Psychosom"},{"key":"897_CR51","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1111\/j.1360-0443.2006.01494.x","volume":"101","author":"DG Critchlow","year":"2006","unstructured":"Critchlow DG. A case of ketamine dependence with discontinuation symptoms. Addict Abingdon Engl. 2006;101:1212\u20133.","journal-title":"Addict Abingdon Engl"},{"key":"897_CR52","first-page":"31","volume":"44","author":"DK Lim","year":"2003","unstructured":"Lim DK. Ketamine associated psychedelic effects and dependence. Singapore Med J. 2003;44:31\u20134.","journal-title":"Singapore Med J"},{"key":"897_CR53","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1097\/00000542-198711000-00054","volume":"67","author":"H Kamaya","year":"1987","unstructured":"Kamaya H, Krishna PR. Ketamine addiction. Anesthesiology. 1987;67:861\u20132.","journal-title":"Anesthesiology"},{"key":"897_CR54","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1177\/0310057X0203000323","volume":"30","author":"HR Pal","year":"2002","unstructured":"Pal HR, Berry N, Kumar R, Ray R. Ketamine dependence. Anaesth Intensive Care. 2002;30:382\u20134.","journal-title":"Anaesth Intensive Care"},{"key":"897_CR55","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S0140-6736(07)60464-4","volume":"369","author":"D Nutt","year":"2007","unstructured":"Nutt D, King LA, Saulsbury W, Blakemore C. Development of a rational scale to assess the harm of drugs of potential misuse. Lancet Lond Engl. 2007;369:1047\u201353.","journal-title":"Lancet Lond Engl"},{"key":"897_CR56","unstructured":"World Health Organization. Fact file on ketamine [Internet]; 2016 [cited 2021 Jan 31]. https:\/\/www.who.int\/medicines\/news\/20160309_FactFile_Ketamine.pdf."},{"key":"897_CR57","unstructured":"Orhurhu VJ, Claus LE, Vashisht R, Cohen SP. Ketamine Toxicity. StatPearls [Internet]. Treasure Island: StatPearls Publishing; 2020 [cited 2020 Sep 28]. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK541087\/."},{"key":"897_CR58","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1360-0443.2011.03576.x","volume":"107","author":"CJA Morgan","year":"2012","unstructured":"Morgan CJA, Curran HV, Independent Scientific Committee on Drugs. Ketamine use: a review. Addict Abingdon Engl. 2012;107:27\u201338.","journal-title":"Addict Abingdon Engl"},{"key":"897_CR59","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2147\/SAR.S15458","volume":"2","author":"J-H Li","year":"2011","unstructured":"Li J-H, Vicknasingam B, Cheung Y-W, Zhou W, Nurhidayat AW, Jarlais DCD, et al. To use or not to use: an update on licit and illicit ketamine use. Subst Abuse Rehabil. 2011;2:11\u201320.","journal-title":"Subst Abuse Rehabil."},{"key":"897_CR60","volume":"12","author":"MWB Zhang","year":"2017","unstructured":"Zhang MWB, Hong YX, Husain SF, Harris KM, Ho RCM. Analysis of print news media framing of ketamine treatment in the United States and Canada from 2000 to 2015. PLoS\u00a0One. 2017;12: e0173202.","journal-title":"PLoS\u00a0One"},{"key":"897_CR61","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1111\/acem.13502","volume":"25","author":"N Karlow","year":"2018","unstructured":"Karlow N, Schlaepfer CH, Stoll CRT, Doering M, Carpenter CR, Colditz GA, et al. A systematic review and meta-analysis of ketamine as an alternative to opioids for acute pain in the emergency department. Acad Emerg Med. 2018;25:1086\u201397.","journal-title":"Acad Emerg Med"},{"key":"897_CR62","volume":"11","author":"EN Lee","year":"2016","unstructured":"Lee EN, Lee JH. The effects of low-dose ketamine on acute pain in an emergency setting: a systematic review and meta-analysis. PLoS\u00a0One. 2016;11: e0165461.","journal-title":"PLoS\u00a0One"},{"key":"897_CR63","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/AAP.0000000000000756","volume":"43","author":"ES Schwenk","year":"2018","unstructured":"Schwenk ES, Viscusi ER, Buvanendran A, Hurley RW, Wasan AD, Narouze S, et al. Consensus guidelines on the use of intravenous ketamine infusions for acute pain management from the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists. Reg Anesth Pain Med. 2018;43:456\u201366.","journal-title":"Reg Anesth Pain Med"},{"key":"897_CR64","first-page":"521","volume":"43","author":"SP Cohen","year":"2018","unstructured":"Cohen SP, Bhatia A, Buvanendran A, Schwenk ES, Wasan AD, Hurley RW, et al. Consensus guidelines on the use of intravenous ketamine infusions for chronic pain from the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists. Reg Anesth Pain Med. 2018;43:521\u201346.","journal-title":"Reg Anesth Pain Med"},{"key":"897_CR65","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1080\/14737175.2019.1640604","volume":"19","author":"J Swainson","year":"2019","unstructured":"Swainson J, Thomas RK, Archer S, Chrenek C, MacKay M-A, Baker G, et al. Esketamine for treatment resistant depression. Expert Rev Neurother. 2019;19:899\u2013911.","journal-title":"Expert Rev Neurother"},{"key":"897_CR66","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1080\/02791072.2015.1072653","volume":"47","author":"U Bonnet","year":"2015","unstructured":"Bonnet U. Long-term ketamine self-injections in major depressive disorder: focus on tolerance in ketamine\u2019s antidepressant response and the development of ketamine addiction. J Psychoactive Drugs. 2015;47:276\u201385.","journal-title":"J Psychoactive Drugs"},{"key":"897_CR67","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1176\/appi.ajp.2015.15081082","volume":"173","author":"KM Schak","year":"2016","unstructured":"Schak KM, Vande Voort JL, Johnson EK, Kung S, Leung JG, Rasmussen KG, et al. Potential risks of poorly monitored ketamine use in depression treatment. Am J Psychiatry. 2016;173:215\u20138.","journal-title":"Am J Psychiatry"},{"key":"897_CR68","first-page":"779","volume":"151","author":"PH Hurt","year":"1994","unstructured":"Hurt PH, Ritchie EC. A case of ketamine dependence. Am J Psychiatry. 1994;151:779.","journal-title":"Am J Psychiatry"},{"key":"897_CR69","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jad.2019.11.028","volume":"263","author":"EE Acevedo-Diaz","year":"2020","unstructured":"Acevedo-Diaz EE, Cavanaugh GW, Greenstein D, Kraus C, Kadriu B, Zarate CA, et al. Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression. J Affect Disord. 2020;263:568\u201375.","journal-title":"J Affect Disord"},{"key":"897_CR70","doi-asserted-by":"crossref","first-page":"17m11731","DOI":"10.4088\/JCP.17m11731","volume":"79","author":"ST Wilkinson","year":"2018","unstructured":"Wilkinson ST, Katz RB, Toprak M, Webler R, Ostroff RB, Sanacora G. Acute and longer-term outcomes using ketamine as a clinical treatment at the Yale Psychiatric Hospital. J Clin Psychiatry. 2018;79:17m11731.","journal-title":"J Clin Psychiatry"},{"key":"897_CR71","doi-asserted-by":"crossref","first-page":"19m12891","DOI":"10.4088\/JCP.19m12891","volume":"81","author":"E Wajs","year":"2020","unstructured":"Wajs E, Aluisio L, Holder R, Daly EJ, Lane R, Lim P, et al. Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: assessment of long-term safety in a phase 3, open-label study (SUSTAIN-2). J Clin Psychiatry. 2020;81:19m12891.","journal-title":"J Clin Psychiatry"},{"key":"897_CR72","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/ajad.12978","volume":"29","author":"L-Y Chen","year":"2020","unstructured":"Chen L-Y, Chen C-K, Chen C-H, Chang H-M, Huang M-C, Xu K. Association of craving and depressive symptoms in ketamine-dependent patients undergoing withdrawal treatment. Am J Addict. 2020;29:43\u201350.","journal-title":"Am J Addict"},{"key":"897_CR73","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/JAN.0000000000000060","volume":"26","author":"HJ Liang","year":"2015","unstructured":"Liang HJ, Tang KL, Chan F, Ungvari GS, Tang WK. Ketamine users have high rates of psychosis and\/or depression. J Addict Nurs. 2015;26:8\u201313.","journal-title":"J Addict Nurs"},{"key":"897_CR74","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1111\/add.14596","volume":"114","author":"P Brenner","year":"2019","unstructured":"Brenner P, Brandt L, Li G, DiBernardo A, Bod\u00e9n R, Reutfors J. Treatment-resistant depression as risk factor for substance use disorders-a nation-wide register-based cohort study. Addict Abingdon Engl. 2019;114:1274\u201382.","journal-title":"Addict Abingdon Engl"},{"key":"897_CR75","doi-asserted-by":"crossref","first-page":"633","DOI":"10.3389\/fpsyt.2018.00633","volume":"9","author":"M-C Huang","year":"2018","unstructured":"Huang M-C, Chen L-Y, Chang H-M, Liang X-Y, Chen C-K, Cheng W-J, et al. Decreased blood levels of oxytocin in ketamine-dependent patients during early abstinence. Front Psychiatry. 2018;9:633.","journal-title":"Front Psychiatry."},{"issue":"1","key":"897_CR76","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00213-019-05342-9","volume":"237","author":"M-C Huang","year":"2020","unstructured":"Huang M-C, Chen C-H, Chen L-Y, Chang H-M, Chen C-K, Lin S-K, et al. Chronic ketamine abuse is associated with orexin-A reduction and ACTH elevation.\u00a0J Psychopharmacol\u00a0(Berl). 2020;237(1):45\u201353.","journal-title":"J Psychopharmacol\u00a0(Berl)"},{"key":"897_CR77","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3389\/fpsyt.2018.00088","volume":"9","author":"Y Liao","year":"2018","unstructured":"Liao Y, Johnson M, Qi C, Wu Q, Xie A, Liu J, et al. Cue-induced brain activation in chronic ketamine-dependent subjects, cigarette smokers, and healthy controls: a task functional magnetic resonance imaging study. Front Psychiatry. 2018;9:88.","journal-title":"Front Psychiatry."},{"key":"897_CR78","first-page":"41","volume":"8","author":"BK Ahmedani","year":"2011","unstructured":"Ahmedani BK. Mental health stigma: society, individuals, and the profession. J Soc Work Values Ethics. 2011;8:41\u2013416.","journal-title":"J Soc Work Values Ethics"},{"key":"897_CR79","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1080\/18374905.2014.11081898","volume":"12","author":"AE Sickel","year":"2014","unstructured":"Sickel AE, Seacat JD, Nabors NA. Mental health stigma update: a review of consequences. Adv Ment Health Routledge. 2014;12:202\u201315.","journal-title":"Adv Ment Health Routledge"},{"key":"897_CR80","volume":"4","author":"R Agabio","year":"2018","unstructured":"Agabio R, Trogu E, Pani PP. Antidepressants for the treatment of people with co-occurring depression and alcohol dependence. Cochrane Database Syst Rev. 2018;4: CD008581.","journal-title":"Cochrane Database Syst Rev"},{"key":"897_CR81","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1176\/appi.ajp.2019.19040423","volume":"176","author":"AF Schatzberg","year":"2019","unstructured":"Schatzberg AF. A word to the wise about intranasal esketamine. Am J Psychiatry. 2019;176:422\u20134.","journal-title":"Am J Psychiatry"},{"key":"897_CR82","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1176\/appi.ajp.2018.18020138","volume":"175","author":"NR Williams","year":"2018","unstructured":"Williams NR, Heifets BD, Blasey C, Sudheimer K, Pannu J, Pankow H, et al. Attenuation of antidepressant effects of ketamine by opioid receptor antagonism. Am J Psychiatry. 2018;175:1205\u201315.","journal-title":"Am J Psychiatry"},{"key":"897_CR83","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1001\/jamapsychiatry.2018.3990","volume":"76","author":"G Yoon","year":"2019","unstructured":"Yoon G, Petrakis IL, Krystal JH. Association of combined naltrexone and ketamine with depressive symptoms in a case series of patients with depression and alcohol use disorder. JAMA Psychiatry. 2019;76:337\u20138.","journal-title":"JAMA Psychiatry"},{"key":"897_CR84","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3389\/fpsyt.2018.00277","volume":"9","author":"JL Jones","year":"2018","unstructured":"Jones JL, Mateus CF, Malcolm RJ, Brady KT, Back SE. Efficacy of ketamine in the treatment of substance use disorders: a systematic review. Front Psychiatry. 2018;9:277.","journal-title":"Front Psychiatry"},{"key":"897_CR85","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.neuropharm.2018.01.005","volume":"142","author":"E Dakwar","year":"2018","unstructured":"Dakwar E, Nunes EV, Hart CL, Hu MC, Foltin RW, Levin FR. A sub-set of psychoactive effects may be critical to the behavioral impact of ketamine on cocaine use disorder: results from a randomized, controlled laboratory study. Neuropharmacology. 2018;142:270\u20136.","journal-title":"Neuropharmacology"},{"key":"897_CR86","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.biopsych.2013.08.009","volume":"76","author":"E Dakwar","year":"2014","unstructured":"Dakwar E, Levin F, Foltin RW, Nunes EV, Hart CL. The effects of subanesthetic ketamine infusions on motivation to quit and cue-induced craving in cocaine-dependent research volunteers. Biol Psychiatry. 2014;76:40\u20136.","journal-title":"Biol Psychiatry"},{"key":"897_CR87","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1176\/appi.ajp.2019.18101123","volume":"176","author":"E Dakwar","year":"2019","unstructured":"Dakwar E, Nunes EV, Hart CL, Foltin RW, Mathew SJ, Carpenter KM, et al. A single ketamine infusion combined with mindfulness-based behavioral modification to treat cocaine dependence: a randomized clinical trial. Am J Psychiatry. 2019;176:923\u201330.","journal-title":"Am J Psychiatry"},{"key":"897_CR88","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0740-5472(02)00275-1","volume":"23","author":"E Krupitsky","year":"2002","unstructured":"Krupitsky E, Burakov A, Romanova T, Dunaevsky I, Strassman R, Grinenko A. Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up. J Subst Abuse Treat. 2002;23:273\u201383.","journal-title":"J Subst Abuse Treat"},{"key":"897_CR89","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/02791072.2007.10399860","volume":"39","author":"EM Krupitsky","year":"2007","unstructured":"Krupitsky EM, Burakov AM, Dunaevsky IV, Romanova TN, Slavina TY, Grinenko AY. Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence. J Psychoactive Drugs. 2007;39:13\u20139.","journal-title":"J Psychoactive Drugs"},{"key":"897_CR90","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1186\/s12888-016-1112-2","volume":"16","author":"L Lalanne","year":"2016","unstructured":"Lalanne L, Nicot C, Lang J-P, Bertschy G, Salvat E. Experience of the use of ketamine to manage opioid withdrawal in an addicted woman: a case report. BMC Psychiatry. 2016;16:395.","journal-title":"BMC Psychiatry"},{"key":"897_CR91","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.neuropharm.2018.01.017","volume":"142","author":"I Ivan Ezquerra-Romano","year":"2018","unstructured":"Ivan Ezquerra-Romano I, Lawn W, Krupitsky E, Morgan CJA. Ketamine for the treatment of addiction: evidence and potential mechanisms. Neuropharmacology. 2018;142:72\u201382.","journal-title":"Neuropharmacology"},{"key":"897_CR92","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1017\/ipm.2020.54","volume":"37","author":"M O\u2019Brien","year":"2020","unstructured":"O\u2019Brien M, McNicholas F. The use of telepsychiatry during COVID-19 and beyond. Ir J Psychol Med. 2020;37:250\u20135.","journal-title":"Ir J Psychol Med"},{"key":"897_CR93","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1093\/jamia\/ocaa284","volume":"28","author":"JM Ferguson","year":"2021","unstructured":"Ferguson JM, Jacobs J, Yefimova M, Greene L, Heyworth L, Zulman DM. Virtual care expansion in the Veterans Health Administration during the COVID-19 pandemic: clinical services and patient characteristics associated with utilization. J Am Med Inform Assoc. 2021;28:453\u201362.","journal-title":"J Am Med Inform Assoc"},{"key":"897_CR94","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12910-016-0087-3","volume":"17","author":"MW Zhang","year":"2016","unstructured":"Zhang MW, Harris KM, Ho RC. Is off-label repeat prescription of ketamine as a rapid antidepressant safe? Controversies, ethical concerns, and legal implications. BMC Med Ethics. 2016;17:4.","journal-title":"BMC Med Ethics"},{"key":"897_CR95","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1176\/appi.ajp.2019.19060631","volume":"176","author":"R McShane","year":"2019","unstructured":"McShane R, Baldwin DS, McAllister-Williams RH, Stone JM, Taylor D, Winstock AR, et al. Esketamine and the need for a new type of registry for drugs with abuse potential. Am J Psychiatry. 2019;176:966\u2013966.","journal-title":"Am J Psychiatry"},{"key":"897_CR96","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jad.2020.01.120","volume":"266","author":"B Short","year":"2020","unstructured":"Short B, Dong V, G\u00e1lvez V, Vulovic V, Martin D, Bayes AJ, et al. Development of the Ketamine Side Effect Tool (KSET). J Affect Disord. 2020;266:615\u201320.","journal-title":"J Affect Disord"},{"key":"897_CR97","unstructured":"Assessment of Abuse Potential of Drugs Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) January 2017; 2017."},{"issue":"1","key":"897_CR98","doi-asserted-by":"crossref","first-page":"100018","DOI":"10.1016\/j.psycom.2021.100018","volume":"2","author":"J Wang","year":"2022","unstructured":"Wang J, Khullar A, McIntyre R, Swainson J. The Drug Liking and Craving Questionnaire (DLCQ) to evaluate addiction risk for ketamine and esketamine.\u00a0Psychiatry Res Com. 2022;2(1):100018.","journal-title":"Psychiatry Res Com"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-022-00897-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-022-00897-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-022-00897-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T06:57:09Z","timestamp":1647413829000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-022-00897-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,14]]},"references-count":98,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["897"],"URL":"https:\/\/doi.org\/10.1007\/s40263-022-00897-2","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,14]]},"assertion":[{"value":"9 January 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The University of Alberta funded open access publication of this article. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare that there is no conflict of interest related to this work. In the past 36\u00a0months, the authors disclose the following: JS has accepted speaker and\/or consulting fees from Allergan\/AbbVie, Bausch, Janssen, Eisai, Lundbeck, Otsuka, ICRE, and Sunovion, has participated on a data safety monitoring board or advisory board for Eisai and Janssen, and the Newly Institute, and owns stock or stock options in the Newly Institute. LK has accepted speaker and\/consulting fees from Allergan, Biron, BMS, Elvium, Janssen, Lundbeck, Otsuka, Sunovion, Takeda, Tilray, the Canadian Psychiatric Association, and the International College of Neuropsychopharmacology (CINP), and has participated on a data safety monitoring board or advisory board for Allergan, Biron, BMS, Elvium, Janssen, Lundbeck, Otsuka, Sunovion, Takeda, and Tilray. SB has accepted speaker and\/or consulting fees from Janssen-Ortho, Shire, Purdue, Otsuka, Pfizer, and Lundbeck, and has participated on a data safety monitoring board or advisory board for Janssen-Ortho, Shire, Purdue, and Otsuka. PC has received grants from Allergan, Janssen, Takeda, and Telus, and has accepted speaker and\/or consulting fees from Allergan, Lundbeck, Janssen, Otsuka, Purdue, Sunovion, and Takeda. MK has received grants from AbbVie, Aleafia, Biron, Canopy, Lundbeck, Janssen, Eli Lilly, Pfizer, and Takeda, and has accepted speaker and\/or consulting fees from AbbVie, Aleafia Cannabis, Allergan, Bausch Health, Biron, Canopy, Eisai, Elvium, Empower Cannabis, Lundbeck, Janssen, Eli Lilly, Novartis, Merck, Otsuka, Pfizer, Purdue, Sante Cannabis, Shire, Sunovion, Takeda, and Tilray. RT has received grants from the Canadian Institutes of Health Research (CIHR), SUAP Health Canada, Alberta Innovates, and CAN Health Network, has accepted speaker and\/or consulting fees from Master Clinician Alliance, has a leadership or fiduciary role in the Pain Society of Alberta and the Canadian Society of Addiction Medicine, owns stocks or stock options in the Newly Institute, and is the Chief Medical Officer of the Newly Institute. AK has accepted speaker and\/or consulting fees from Lundbeck, Otsuka, Sunovion, Eisai, Elvium, Bausch, Purdue, AbbVie, Spectrum, Tilray, and Pfizer, has participated on a data safety monitoring board or advisory board for Eisai, Sunovion, Lundbeck, Otsuka, Bausch, Purdue, AbbVie, Spectrum, Tilray, and the Newly Institute, and owns stock or stock options in the Newly Institute.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"JS and AK conceptualized the idea for this article and contributed to the literature search and writing of the manuscript. JS, AK, LK, SB, PC, MK, and RT contributed to the outline of the paper, critical evaluation of and application of the relevant literature identified, manuscript revisions, and recommendations made for clinical practice. All authors approved the manuscript for submission and are accountable for this work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}